The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | An update on kinase inhibitors from EHA 2017
Barbara Eichhorst
• 23 Jun 2017
Barbara Eichhorst, MD from University Clinic of Cologne,
Germany, gives us an update on kinase inhibitors both in development and in the clinic. She discusses ibrutinib long-term follow-up data, idelalisib combined with rituximab and venetoxlax.
